Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
  • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D497/04—Ortho-condensed systems

Definitions

• the present invention relates to a method for producing an industrially producible aromatic dihalogen compound.
• Aromatic dihalogen compounds are useful compounds used as organic electronic materials.
• an aromatic dihalogen compound is synthesized by reacting an aromatic diamine compound with a halogenating agent such as iodine or cupric bromide in the presence of tert-butyl nitrite at room temperature.
• a halogenating agent such as iodine or cupric bromide
• Patent Documents 1 and 2 required the use of the designated drug tert-butyl nitrite. Since tert-butyl nitrite is a designated drug, it is subject to very strict controls and is highly toxic. Therefore, it has been desired to develop a reaction capable of obtaining a highly pure aromatic dihalogen compound using a nitrite which is not a designated drug.
• an object of the present invention is to provide an industrial production method capable of obtaining a highly pure aromatic dihalogen compound using a nitrite ester compound that is not a designated drug.
• the present inventors have completed the present invention as a result of intensive studies to achieve this purpose. That is, it is a production method for obtaining an aromatic dihalogen compound using one or more selected from the group consisting of ethyl nitrite, hexyl nitrite and amyl nitrite, which are not designated drugs, among nitrite ester compounds.
• the nitrite compound is one or more selected from the group consisting of ethyl nitrite, hexyl nitrite and amyl nitrite
• a method for producing an aromatic dihalogen compound comprising reaction step 1, wherein the reaction is performed at a reaction temperature of 35°C or higher.
• the method for producing an aromatic dihalogen compound according to [1] which includes, after the reaction step 1, a reaction step 2 at a temperature higher than that of the reaction step 1.
• each X independently represents a halogen.
• the halogenating agent is one or more selected from the group consisting of iodine, bromine, chlorine, copper halides and quaternary ammonium halide salts. A method for producing the described aromatic dihalogen compound.
• tett-butyl nitrite which is a designated drug with high toxicity and strict control
• an aromatic diamine compound with a nitrite ester compound that is not a designated drug under appropriate conditions. After that, a highly pure aromatic dihalogen compound can be industrially obtained.
• the method for producing an aromatic dihalogen compound of the present invention comprises reacting an aromatic diamine compound, a nitrite compound and a halogenating agent, wherein the nitrite compound is prepared from ethyl nitrite, hexyl nitrite and amyl nitrite. It is characterized by being one or more selected from the group consisting of (hereinafter also referred to as a specific nitrite compound).
• the aromatic diamine compound is not particularly limited as long as it is a compound having an aromatic ring and two amino groups, but is preferably a compound in which two amino groups are directly bonded to an aromatic ring, more preferably a compound of the general formula (1 ) is a compound shown in
• the aromatic dihalogen compound is not particularly limited as long as it is a compound having an aromatic ring and two halogens, but is preferably a compound in which two halogens are directly bonded to the aromatic ring, more preferably general formula (2) It is a compound shown in The aromatic diamine compound and the aromatic dihalogen compound preferably have corresponding structures.
• each R is independently hydrogen, halogen or an alkyl group.
• Halogen in R is preferably iodine, bromine or chlorine.
• the alkyl group may be linear or branched, and preferably has 1-30 carbon atoms, more preferably 5-20 carbon atoms.
• Each A is independently nitrogen or oxygen. Both A's are preferably nitrogen or oxygen, and more preferably both A's are nitrogen.
• R and A are as defined above, and each X is independently halogen.
• Halogen in X is preferably iodine, bromine or chlorine.
• an aromatic diamine, a halogenating agent, and a nitrite ester compound are put into a reaction vessel and reacted.
• nitrite ester compound it is necessary to use one or more selected from the group consisting of ethyl nitrite, hexyl nitrite and amyl nitrite.
• drugs are not designated drugs.
• a designated drug is defined as a drug that excites or depresses the central nervous system or has a hallucinogenic effect (including the effect of maintaining or enhancing such effect) according to the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices. It is defined as a substance that has a high probability of causing health hazards when used on the human body, and is related to ensuring the quality, efficacy and safety of pharmaceuticals and medical devices.
• tert-butyl nitrite is a designated drug under Japanese laws and regulations, and although the laws and regulations differ from country to country, it is required to avoid its use in any case because of its toxicity. On the other hand, when the specific nitrite compound is used, complicated and sophisticated storage management rules are not required, and special detoxification equipment is not required, and can be safely handled.
• the specific nitrite compounds may be used alone, or two or more of them may be used in combination.
• the amount of the specific nitrite compound used is preferably 1.5 mol or more per 1 mol of the aromatic diamine compound. It is more preferably 2 mol or more, still more preferably 2.5 mol or more, because the reaction rate can be improved and the reaction time can be expected to be shortened. Also, even if it is used too excessively, the effect of improving the reaction rate is saturated, and the post-treatment process may become complicated. less than a mole.
• the total amount is calculated as the specific nitrite compound amount.
• a common halogenating agent can be used as the halogenating agent.
• iodine, bromine, chlorine, copper halide, quaternary ammonium halide salts, N-halogenated succinimide and the like are preferred, and iodine, bromine, chlorine, copper halide and quaternary ammonium halide salts are preferred.
• One or more selected from the group consisting of is particularly preferred.
• the copper halide is not particularly limited, and includes cuprous chloride, cupric chloride, cuprous bromide, cupric bromide, cuprous iodide and the like. Copper is preferred.
• Halide salts of quaternary ammonium include tetrabutylammonium bromide (TBAB), tetrabutylammonium chloride (TBAC), tetrabutylammonium iodide (TBAI), and the like.
• N-halogenated succinimide include N-bromosuccinimide (NBS), N-chlorosuccinimide (NCS), N-iodosuccinimide (NIS) and the like.
• the halogenating agent may be used alone, or two or more of them may be used in combination.
• the amount of the halogenating agent to be used is preferably 1.5 mol to 6 mol, more preferably 2 mol to 4 mol, per 1 mol of the aromatic diamine compound.
• an organic sulfonic acid compound may be used in combination to promote halogenation.
• the organic sulfonic acid compound is not particularly limited, and includes p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid and the like.
• the amount is preferably 1.5 mol to 6 mol, more preferably 2 mol to 4 mol, per 1 mol of the aromatic diamine compound.
• a solvent may be used in this reaction. It is important that the solvent used in this reaction should not interfere with the reaction. Preferred specific examples include acetonitrile (AN), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide (DMAc), N-methyl-2-pyrrolidone (NMP), chloroform, ethyl acetate, hexane, heptane, toluene, tetrahydrofuran and the like. These solvents may be used alone or in combination of two or more. The amount of the solvent used is preferably 2 to 100 parts by mass, more preferably 4 to 50 parts by mass, and still more preferably 6 to 30 parts by mass, relative to 1 part by mass of the aromatic diamine compound. .
• reaction step 1 in which the reaction temperature is 35°C or higher.
• the reaction temperature in reaction step 1 is preferably 40° C. or higher, more preferably 45° C. or higher. Also, it is preferably 70°C or lower, more preferably 60°C or lower, and still more preferably lower than 60°C.
• the reaction time of reaction step 1 is preferably 30 minutes or longer, more preferably 1 hour or longer, and still more preferably 2 hours or longer. Also, it is preferably 5 hours or less, more preferably 4 hours or less, and still more preferably 3 hours or less.
• a high-quality aromatic dihalogen compound can be obtained by including reaction step 1 under the above conditions.
• reaction step 2 it is preferable to include a reaction step 2 at a higher temperature than the reaction step 1 after the reaction step 1.
• the reaction temperature of reaction step 2 is not limited as long as it is higher than that of reaction step 1, but is preferably 60° C. or higher, more preferably 70° C. or higher, and still more preferably 80° C. or higher. Also, it is preferably 130° C. or lower, more preferably 120° C. or lower, and still more preferably 110° C. or lower.
• the reaction time of reaction step 2 is preferably 1 hour or longer, more preferably 3 hours or longer, and still more preferably 5 hours or longer.
• reaction step 2 it is preferably 20 hours or less, more preferably 18 hours or less, and still more preferably 16 hours or less.
• the difference in reaction temperature between the reaction step 1 and the reaction step 2 is preferably 25°C or higher, more preferably 30°C or higher, and still more preferably 40°C or higher. Also, it is preferably 90° C. or lower, more preferably 80° C. or lower, and still more preferably 70° C. or lower.
• the aromatic dihalogen compound produced is preferably subjected to solid-liquid separation such as filtration.
• a crude product can be easily obtained by solid-liquid separation.
• the crude product is preferably purified by crystallization, suspension washing, recrystallization, etc. By performing the purification, a highly pure aromatic dihalogen compound can be obtained.
• the same solvent as the reaction solvent can be used for the suspension washing.
• DMSO, NMP, DMF, DMAc, etc. can be used as the recrystallization solvent.
• HPLC high performance liquid chromatography
• Example 2 2,6-Dibromobenzo[1,2-d:4,5-d']bisthiazole
• 2,6-dibromobenzo[1 ,2-d:4,5-d']bisthiazoles were prepared. Table 1 shows the results.
• Example 3 2,6-Dibromobenzo[1,2-d:4,5-d′]bisthiazole
• 2,6-dibromobenzo[1 ,2-d:4,5-d']bisthiazoles were prepared. Table 1 shows the results.
• Example 4 2,6-Diiodobenzo[1,2-d:4,5-d′]bisthiazole In the same manner as in Example 1, using the reagents listed in Table 1, 2,6-diiodobenzo[1,2-d:4,5-d′]bisthiazole 1,2-d:4,5-d']bisthiazoles were prepared. Table 1 shows the results.
• Example 5 2,6-dibromobenzo[1,2-d:4,5-d′]bisthiazole A 200 ml flask was charged with acetonitrile (63.0 g), p-toluenesulfonic acid monohydrate (16.4 g, 86 .3 mmol), tetrabutylammonium bromide (46.4 g, 143.9 mmol), benzo[1,2-d:4,5-d′]bisthiazole-2,6-diamine (8.0 g, 36.0 mmol). ), cupric bromide (0.24 g, 1.0 mmol) was added and stirred at 20° C. for 15 minutes.
• Example 7 2,6-Dibromobenzo[1,2-d:4,5-d']bisthiazole
• 2,6-dibromobenzo[1 ,2-d:4,5-d']bisthiazoles were prepared. Table 1 shows the results.
• Examples 1 to 7 a nitrite compound, which is not a designated drug, was used and produced under appropriate reaction conditions, so a high-purity aromatic dihalogen compound could be produced safely.
• the reaction temperature was low and the purity of the aromatic dihalogen compound was low.
• tert-butyl nitrite was used in Comparative Example 2, the quality deteriorated, and since it is a designated drug, there is a safety problem. Therefore, for industrial mass use, it is necessary to install drug control and abatement equipment, which is complicated.
• a high-purity aromatic dihalogen compound can be safely obtained using a nitrite compound that is not a designated drug.
• the aromatic dihalogen compound obtained by the production method of the present invention is an important skeleton component for Suzuki cross-coupling reaction and Heck-type reaction. These are useful compounds utilized as organic electronic materials.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84919971

Family Applications (1)

Country Status (6)

Citations (6)

Family Cites Families (3)

• 2022
  • 2022-05-23 JP JP2023535158A patent/JPWO2023286454A1/ja active Pending
  • 2022-05-23 CN CN202280047863.7A patent/CN117651704A/zh active Pending
  • 2022-05-23 US US18/576,202 patent/US20240368187A1/en not_active Abandoned
  • 2022-05-23 KR KR1020247004354A patent/KR20240035518A/ko active Pending
  • 2022-05-23 EP EP22841801.8A patent/EP4371990A4/en not_active Withdrawn
  • 2022-05-23 WO PCT/JP2022/021138 patent/WO2023286454A1/ja not_active Ceased

Patent Citations (7)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events